The immunotherapy treatment — called talquetamab — successfully treated 73 percent of patients with multiple myeloma in a global trial.
It helped people who had relapsed in their disease more than once after other treatments failed to bring them into remission for an extended period of time. The Daily Mail
See also:
- GPRC5D-Targeted CAR T Cells for Myeloma (abstract) New England Journal of Medicine
No comments:
Post a Comment